|
1
|
Ramachandran R, Junnuthula VR, Gowd GS,
Ashokan A, Thomas J, Peethambaran R, Thomas A, Unni AK, Panikar D,
Nair SV and Koyakutty M: Theranostic 3-Dimensional nano
brain-implant for prolonged and localized treatment of recurrent
glioma. Sci Rep. 7:432712017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malhotra M, Sekar TV, Ananta JS,
Devulapally R, Afjei R, Babikir HA, Paulmurugan R and Massoud TF:
Targeted nanoparticle delivery of therapeutic antisense microRNAs
presensitizes glioblastoma cells to lower effective doses of
temozolomide in vitro and in a mouse model. Oncotarget.
9:21478–21494. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wong ET, Hess KR, Gleason MJ, Jaeckle KA,
Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and
prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol. 17:2572–2578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamborn KR, Yung WK, Chang SM, Wen PY,
Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink
KL, et al: Progression-free survival: An important end point in
evaluating therapy for recurrent high-grade gliomas. Neuro Oncol.
10:162–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmalz PG, Shen MJ and Park JK: Treatment
resistance mechanisms of malignant glioma tumor stem cells. Cancers
(Basel). 3:621–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee RC, Feinbaum RL and Ambros V: The C.
Elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan AA, Advani J, Patel K, Nanjappa V,
Datta KK, Solanki HS, Kumar P, Mathur PP, Nair B, Keshava Prasad
TS, et al: Chronic exposure to cigarette smoke and chewing tobacco
alters expression of microRNAs in esophageal epithelial cells.
Microrna. 7:28–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tong D, Zhao L, He K, Sun H, Cai D, Ni L,
Sun R, Chang S, Song T and Huang C: MECP2 promotes the growth of
gastric cancer cells by suppressing miR-338-mediated
antiproliferative effect. Oncotarget. 7:34845–34859. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang L, Gao L, Zou XP, Huang ML, Chen G,
Li JJ and Cai XY: Diagnostic significance and potential function of
miR-338-5p in hepatocellular carcinoma: A bioinformatics study with
microarray and RNA sequencing data. Mol Med Rep. 17:2297–2312.
2018.PubMed/NCBI
|
|
14
|
Besse A, Sana J, Lakomy R, Kren L, Fadrus
P, Smrcka M, Hermanova M, Jancalek R, Reguli S, Lipina R, et al:
MiR-338-5p sensitizes glioblastoma cells to radiation through
regulation of genes involved in DNA damage response. Tumour Biol.
37:7719–7727. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lei D, Zhang F, Yao D, Xiong N, Jiang X
and Zhao H: MiR-338-5p suppresses proliferation, migration,
invasion, and promote apoptosis of glioblastoma cells by directly
targeting EFEMP1. Biomed Pharmacother. 89:957–965. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang XH, Wang Q, Chen JS, Fu XH, Chen XL,
Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, et al: Bead-based microarray
analysis of microRNA expression in hepatocellular carcinoma:
miR-338 is downregulated. Hepatol Res. 39:786–794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Shi LY, Lei YM, Bao YH, Li ZY, Ding
F, Zhu GT, Wang QQ and Huang CX: Radiosensitization effect of
hsa-miR-138-2-3p on human laryngeal cancer stem cells. PeerJ.
5:e32332017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma Y, Pan X, Xu P, Mi Y, Wang W, Wu X, He
Q, Liu X, Tang W and An HX: Plasma microRNA alterations between
EGFR-activating mutational NSCLC patients with and without primary
resistance to TKI. Oncotarget. 8:88529–88536. 2017.PubMed/NCBI
|
|
19
|
Zhang JF, Zhang JS, Zhao ZH, Yang PB, Ji
SF, Li N, Shi QD, Tan J, Xu X, Xu CB and Zhao LY: MicroRNA-770
affects proliferation and cell cycle transition by directly
targeting CDK8 in glioma. Cancer Cell Int. 18:1952018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai J, Li Q, Bing Z, Zhang Y, Niu L, Yin
H, Yuan G and Pan Y: Comprehensive analysis of a microRNA
expression profile in pediatric medulloblastoma. Mol Med Rep.
15:4109–4115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eguia-Aguilar P, Gutierrez-Castillo L and
Perezpena-Diazconti M: Expression of microRNAs in tumors of the
central nervous system in pediatric patients in México. Childs Nerv
Syst. 33:2117–2128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu WJ, Shi J, Hu G, Yu X, Lu H, Yang ML,
Liu B and Wu ZX: Wnt/β-catenin signaling inhibits FBXW7 expression
by upregulation of microRNA-770 in hepatocellular carcinoma. Tumour
Biol. 37:6045–6051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu
X, Jiang J, Peng C, Guo GZ and Cui S: MiR-770-5p inhibits cisplatin
chemoresistance in human ovarian cancer by targeting ERCC2.
Oncotarget. 7:53254–53268. 2016.PubMed/NCBI
|
|
24
|
Lian J, Tian H, Liu L, Zhang XS, Li WQ,
Deng YM, Yao GD, Yin MM and Sun F: Downregulation of microRNA-383
is associated with male infertility and promotes testicular
embryonal carcinoma cell proliferation by targeting IRF1. Cell
Death Dis. 1:e942010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Z, Zeng X, Tian D, Xu H, Cai Q, Wang J
and Chen Q: MicroRNA-383 inhibits anchorage-independent growth and
induces cell cycle arrest of glioma cells by targeting CCND1.
Biochem Biophys Res Commun. 453:833–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lü M, Tian H, Cao YX, He X, Chen L, Song
X, Ping P, Huang H and Sun F: Downregulation of
miR-320a/383-sponge-like long non-coding RNA NLC1-C (narcolepsy
candidate-region 1 genes) is associated with male infertility and
promotes testicular embryonal carcinoma cell proliferation. Cell
Death Dis. 6:e19602015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu D, Ma P, Gao G, Gui Y, Niu X and Jin B:
MicroRNA-383 expression regulates proliferation, migration,
invasion, and apoptosis in human glioma cells. Tumour Biol.
36:7743–7753. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu X, Ma C, Fu L, Dong J and Ying J:
MicroRNA-139 inhibits the proliferation, migration and invasion of
gastric cancer cells by directly targeting ρ-associated protein
kinase 1. Oncol Lett. 15:5977–5982. 2018.PubMed/NCBI
|
|
29
|
Su S and Nie X: MiR-139 prompts the
development of osteosarcomas mainly through targeting ROCK1.
Pharmazie. 72:759–763. 2017.PubMed/NCBI
|
|
30
|
Zhang P, Yin J, Yuan L, Bai Q and Lu J:
microRNA-139 suppresses proliferation of hepatocellular carcinoma
cells by silencing of B cell translocation gene 3. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 33:1516–1520. 2017.(In Chinese). PubMed/NCBI
|
|
31
|
Ye Y, Zhuang J, Wang G, He S, Ni J and Xia
W: MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid
carcinoma progression. Oncol Lett. 14:7799–7806. 2017.PubMed/NCBI
|
|
32
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y,
Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1
expression and potentiates TMZ-induced apoptosis in glioma. CNS
Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiao F, Li Y, Wan Y and Xue M:
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based
chemotherapy through regulation of ATP7A/B. Cancer Chemother
Pharmacol. 81:935–947. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo HN, Wang ZH, Sheng Y, Zhang Q, Yan J,
Hou J, Zhu K, Cheng Y, Xu YL, Zhang XH, et al: MiR-139 targets
CXCR4 and inhibits the proliferation and metastasis of laryngeal
squamous carcinoma cells. Med Oncol. 31:7892014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bo LJ, Wei B, Li ZH, Wang ZF, Gao Z and
Miao Z: Bioinformatics analysis of miRNA expression profile between
primary and recurrent glioblastoma. Eur Rev Med Pharmacol Sci.
19:3579–3586. 2015.PubMed/NCBI
|
|
37
|
Lin M, Chen W, Huang J, Gao H, Ye Y, Song
Z and Shen X: MicroRNA expression profiles in human colorectal
cancers with liver metastases. Oncol Rep. 25:739–747.
2011.PubMed/NCBI
|
|
38
|
Kanaan Z, Roberts H, Eichenberger MR,
Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and
Galandiuk S: A plasma microRNA panel for detection of colorectal
adenomas: A step toward more precise screening for colorectal
cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen WC, Lin MS, Ye YL, Gao HJ, Song ZY
and Shen XY: microRNA expression pattern and its alteration
following celecoxib intervention in human colorectal cancer. Exp
Ther Med. 3:1039–1048. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu X, Duan B, Dong Y, He C, Zhou H, Sheng
H, Gao H and Zhang X: MicroRNA-139-3p indicates a poor prognosis of
colon cancer. Int J Clin Exp Pathol. 7:8046–8052. 2014.PubMed/NCBI
|
|
41
|
Yuan GQ, Wei NL, Mu LY, Wang XQ, Zhang YN,
Zhou WN and Pan YW: A 4-miRNAs signature predicts survival in
glioblastoma multiforme patients. Cancer Biomark. 20:443–452. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun
H, Jiang Y, Zhang W, Liang A, Guo Y, et al: miR-139-5p suppresses
cancer cell migration and invasion through targeting ZEB1 and ZEB2
in GBM. Tumour Biol. 36:6741–6749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dai S, Wang X, Li X and Cao Y:
MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and
regulating cell cycle in glioblastoma multiforme. Biochem Biophys
Res Commun. 467:204–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sana J, Radova L, Lakomy R, Kren L, Fadrus
P, Smrcka M, Besse A, Nekvindova J, Hermanova M, Jancalek R, et al:
Risk Score based on microRNA expression signature is independent
prognostic classifier of glioblastoma patients. Carcinogenesis.
35:2756–2762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Westhoff MA, Karpel-Massler G, Brühl O,
Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L and
Debatin KM: A critical evaluation of PI3K inhibition in
glioblastoma and neuroblastoma therapy. Mol Cell Ther. 2:322014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Langhans J, Schneele L, Trenkler N, von
Bandemer H, Nonnenmacher L, Karpel-Massler G, Siegelin MD, Zhou S,
Halatsch ME, Debatin KM and Westhoff MA: The effects of
PI3K-mediated signalling on glioblastoma cell behaviour.
Oncogenesis. 6:3982017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu J, Li Z, Wang J, Chen H and Fang JY:
Combined PTEN mutation and protein expression associate with
overall and disease-free survival of glioblastoma patients. Transl
Oncol. 7:196–205.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: Of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vasudevan KM, Gurumurthy S and Rangnekar
VM: Suppression of PTEN expression by NF-kappa B prevents
apoptosis. Mol Cell Biol. 24:1007–1021. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang X, Trotman LC, Koppie T, Alimonti A,
Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo
C, et al: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.
Cell. 128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ahn Y, Hwang CY, Lee SR, Kwon KS and Lee
C: The tumour suppressor PTEN mediates a negative regulation of the
E3 ubiquitin-protein ligase Nedd4. Biochem J. 412:331–338. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Catanzaro G, Besharat ZM, Miele E,
Chiacchiarini M, Po A, Carai A, Marras CE, Antonelli M, Badiali M,
Raso A, et al: The miR-139-5p regulates proliferation of
supratentorial paediatric low-grade gliomas by targeting the
PI3K/AKT/mTORC1 signalling. Neuropathol Appl Neurobiol. 44:687–706.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Neradugomma NK, Subramaniam D, Tawfik OW,
Goffin V, Kumar TR, Jensen RA and Anant S: Prolactin signaling
enhances colon cancer stemness by modulating Notch signaling in a
Jak2-STAT3/ERK manner. Carcinogenesis. 35:795–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tworoger SS and Hankinson SE: Prolactin
and breast cancer etiology: An epidemiologic perspective. J Mammary
Gland Biol Neoplasia. 13:41–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang TQ, Chen M, Wang YQ, Xu W, Han Y, Xu
J, Xiang YJ, Yuan B, Wang HZ and Zhou YX: Nuclear factor-kappa B1
inhibits early apoptosis of glioma cells by promoting the
expression of Bcl-2. Onco Targets Ther. 10:4305–4313. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kina I, Sultuybek GK, Soydas T, Yenmis G,
Biceroglu H, Dirican A, Uzan M and Ulutin T: Variations in
Toll-like receptor and nuclear factor-kappa B genes and the risk of
glioma. Br J Neurosurg. 33:165–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hayashi S, Yamamoto M, Ueno Y, Ikeda K,
Ohshima K, Soma G and Fukushima T: Expression of nuclear
factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in
human astrocytomas. Neurol Med Chir (Tokyo). 41:187–195. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fels C, Schäfer C, Hüppe B, Bahn H,
Heidecke V, Kramm CM, Lautenschläger C and Rainov NG: Bcl-2
expression in higher-grade human glioma: A clinical and
experimental study. J Neurooncol. 48:207–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai
S, Wang Z, Liu J and Cai G: miR-139-5p inhibits the
epithelial-mesenchymal transition and enhances the chemotherapeutic
sensitivity of colorectal cancer cells by downregulating BCL2. Sci
Rep. 6:271572016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie
L, Ma X, Wang J, Ouyang S, Wu Q, et al: Regulation of Mcl-1 by
constitutive activation of NF-κB contributes to cell viability in
human esophageal squamous cell carcinoma cells. BMC Cancer.
14:982014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Day BW, Stringer BW, Spanevello MD,
Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ,
Brown CL, et al: ELK4 neutralization sensitizes glioblastoma to
apoptosis through downregulation of the anti-apoptotic protein
Mcl-1. Neuro Oncol. 13:1202–1212. 2011. View Article : Google Scholar : PubMed/NCBI
|
